Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rebecca C Larson

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19Maria Ormhøj, Irene Scarfò, Maria L Cabral, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2024
Correction: Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19Maria Ormhøj, Irene Scarfò, Maria L Cabral, et al.
Neuro-Oncology Advances|February 8, 2023
Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastomaAndrea Schmidts, Ambike A Srivastava, Rishab Ramapriyan, et al.
Nature Communications|December 5, 2023
Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screeningAzucena Ramos, Catherine E Koch, Yunpeng Liu-Lupo, et al.
Nature Medicine|September 13, 2022
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphomaNicholas J Haradhvala, Mark B Leick, Katie Maurer, et al.
Nature|September 24, 2025
In vivo CRISPR screens identify modifiers of CAR T cell function in myelomaNelson H Knudsen, Giulia Escobar, Felix Korell, et al.
Journal for Immunotherapy of Cancer|December 30, 2025
Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignanciesAdila Izgutdina, Tasfia Rashid, William C Temple, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2025
Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell MalignanciesAdila Izgutdina, Tasfia Rashid, William C Temple, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2024
Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its StromaMarc Wehrli, Samantha Guinn, Filippo Birocchi, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19Maria Ormhøj, Irene Scarfò, Maria L Cabral, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2024
Correction: Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19Maria Ormhøj, Irene Scarfò, Maria L Cabral, et al.
Neuro-Oncology Advances|February 8, 2023
Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastomaAndrea Schmidts, Ambike A Srivastava, Rishab Ramapriyan, et al.
Nature Communications|December 5, 2023
Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screeningAzucena Ramos, Catherine E Koch, Yunpeng Liu-Lupo, et al.
Nature Medicine|September 13, 2022
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphomaNicholas J Haradhvala, Mark B Leick, Katie Maurer, et al.
Nature|September 24, 2025
In vivo CRISPR screens identify modifiers of CAR T cell function in myelomaNelson H Knudsen, Giulia Escobar, Felix Korell, et al.
Journal for Immunotherapy of Cancer|December 30, 2025
Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignanciesAdila Izgutdina, Tasfia Rashid, William C Temple, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2025
Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell MalignanciesAdila Izgutdina, Tasfia Rashid, William C Temple, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2024
Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its StromaMarc Wehrli, Samantha Guinn, Filippo Birocchi, et al.
Pageof 3